Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 613-624 , December 2007

Pathophysiology of myeloma bone disease

  • G. David Roodman, MD, PhD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-412-688-6571; Fax: +1-412-688-6960.

References 

  1. Roodman GD. Cell Biology of the osteoclast. Experimental Hematology. 1999;27:1229–1241
  2. Roodman GD. Treatment strategies for bone disease. Bone Marrow Transplantation 2007 Aug 6. [Epub ahead of print].
  3. Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006;24:986–991
  4. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator NF-Kappa-B ligand (RANKL). Experimental Hematology. 2004;32:685–691
  5. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96:671–675
  6. Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 2004;103:2308–2315
  7. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:3540–3545
  8. Nakagava N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochemical and Biophysical Research Communications. 1998;253:395–400
  9. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–342
  10. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:3597–3602
  11. Hofbauer LC, Heufelder AE. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. European Journal of Endocrinology. 1998;139:152–154
  12. Tsukii K, Shima N, Mochizuki S, et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochemical and Biophysical Research Communications. 1998;246:337–341
  13. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes & Development. 1999;13:2412–2424
  14. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–176
  15. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319
  16. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes & Development. 1998;12:1260–1268
  17. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:1556–1571
  18. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:11581–11586
  19. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand- osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064–1069
  20. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology. 2002;116:278–290
  21. Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001;97:3349–3353
  22. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood. 2003;101:4998–5005
  23. Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1 alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. British Journal of Haematology. 2004;125:38–41
  24. Alsina M, Boyce B, Devlin RD, et al. Development of an in vivo model of human multiple myeloma bone disease. Blood. 1996;87:1495–1501
  25. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1 alpha block bone destruction in a model of myeloma bone disease. The Journal of Clinical Investigation. 2001;108:1833–1841
  26. Masih-Khan E, Trudel S, Heise C, et al. MIP-1a (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 2006;108:3465–3471
  27. Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005;106:1407–1414
  28. Solary E, Guiguet M, Zeller V, et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. American Journal of Hematology. 1992;39:163–171
  29. Sai HI, Apperley JF, Graves M, et al. Interleukin -6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of unknown significance. British Journal of Haematology. 1998;101:287–295
  30. Karadag A, Oyajobi BO, Apperley JF, et al. Human myeloma cells promote the production of interleukin-6 by primary human osteoblasts. British Journal of Haematology. 2000;108:383–390
  31. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell to cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–2491
  32. Nguyen AN, Sttebbins EG, Henson M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Experimental Cell Research. 2006;312:1909–1923
  33. Vanderkerken K, Medicherla S, Coulton L, et al. Inhibition of p38a MAPK reduces tumor burden, prevents the development of myeloma bone disease, and increases survival in the 5T2 and 5T3 murine models of myeloma. Blood. 2006;108:981a;[abstract 3436]
  34. Kurihara N, Hiruma Y, Hong CS, et al. targeting p62 in marrow stromal cells is effective at inhibiting myeloma cell growth. Blood. 2006;108:155a;[abstract 513]
  35. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology. 1989;7:1909–1914
  36. Bataille R, Chappard D, Marcelli C, et al. Osteoblast stimulation in multiple myeloma lacking bone lytic lesions. British Journal of Haematology. 1990;76:484–487
  37. Hjorth-Hansen H, Seifert MF, Borset M, et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Journal of Bone and Mineral Research. 1999;14:256–263
  38. Kobayashi T, Kronenberg H. Mini review: transcriptional regulation in development of bone. Endocrinology. 2005;146:1012–1017
  39. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfal: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747–754
  40. Franceschi RT, Xiao G. Regulation of the osteoblast specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. Journal of Cellular Biochemistry. 2003;88:446–454
  41. Karsenty G, Ducy P, Starbuck M, et al. Cbfal as a regulator of osteoblast differentiation and function. Bone. 1999;25:107–108
  42. Komori T. Runx2, a multifunctional transcription factor in skeletal development. Journal of Cellular Biochemistry. 2002;87:1–8
  43. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFAL1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106:2472–2483
  44. Thirunavukkarasu K, Halladay DL, Miles RR, et al. The osteoblast-specific transcription factor Cbfal contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. The Journal of Biological Chemistry. 2000;275:25163–25172
  45. Barille S, Collette M, Bataille R, et al. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell to cell contact but downregulate osteocalcin. Blood. 1995;86:3151–3159
  46. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. The American Journal of Pathology. 2002;160:1293–1299
  47. Roodman GD. New Potential targets for treating myeloma bone disease. Clinical Cancer Research. 2006;12:6270s–6273s
  48. Lee SK, Kalinowski JF, Jacquin C, et al. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. Journal of Bone and Mineral Research. 2006;21:695–702
  49. Toraldo G, Roggia C, Qian WP, et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappaB ligand and tumor necrosis factor alpha from T cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:125–130
  50. Qiang Y-W, Endo Y, Rubin JS, et al. Wnt signaling in B cell neoplasia. Oncogene. 2003;22:1536–1545
  51. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein (LRP5) affects bone accrual and eye development. Cell. 2001;107:513–523
  52. Westerndorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19–39
  53. Rawadi G, Vayssiere B, Dunn F, et al. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. Journal of Bone and Mineral Research. 2003;18:1842–1853
  54. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Developmental Cell. 2001;1:423–434
  55. Grotewold L, Ruther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulated programmed cell death. The EMBO Journal. 2002;21:966–975
  56. Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk-1 gene leads to an increase in bone formation and bone mass. Journal of Bone and Mineral Research. 2006;21:934–954
  57. Li J, Sarosi I, Cattley RC, et al. Dkk-1 mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754–766
  58. Tian E, Zhan F, Walker R, et al. The role of Wnt signaling antagonist DKK-1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine. 2003;349:2483–2494
  59. Politou MC, Health DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer. 2006;119:1728–1731
  60. Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell. 2005;8:751–764
  61. Spencer GJ, Utting JC, Etheridge SL, et al. Wnt signaling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. Journal of Cell Science. 2006;119:1283–1296
  62. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor sFRP-2. Blood. 2005;106:3160–3165
  63. Oyajobi BO, Mundy GR. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein 1-alpha and the proteasome. Cancer. 2003;97:813–817
  64. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. The New England Journal of Medicine. 1996;334:448–493
  65. Lacy MQ, Dispenzieri A, Gertz MA, et al. mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic proceedings. 2006;81:1047–1053
  66. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clinical Cancer Research. 2006;12:1221–1228
  67. Mbalaviele G, Anderson G, Jones A, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. The Journal of Pharmacology and Experimental Therapeutics. 2006;317:1044–1053
  68. Rossa C, Ehmann K, Liu M, et al. MKK3/6-p38 MAPK signaling is required for IL-1 beta and TNF alpha induced RANKL expression in bone marrow stromal cells. Journal of Interferon & Cytokine Research. 2006;26:719–729
  69. Zangari M, Yaccoby S, Cavallo F, et al. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clinical Lymphoma & Myeloma. 2006;7:109–114
  70. Heider U, Kaiser M, Muller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European Journal of Haematology. 2006;77:233–238
  71. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. The Journal of Clinical Investigation. 2003;111:1117–1182
  72. Terpos E, Heath D, Rahemtulla A, et al. Bortezomib reduces serum dicckopf-1 and RANKL concentrations and normalizes indices of bone remodeling in patients with relapsed multiple myeloma. Blood. 2006;108:153a;[abstract 506]
  73. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology. 2005;3:272–278
  74. Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma cells. Blood. 2003;101:3568–3573
  75. Pennisi A, Ling W, Perkins P, et al. PTH and Bortezomib suppress growth of primary human myeloma cells through increased bone formation in vivo. Blood. 2006;108:154a;[abstract 509]

PII: S1521-6926(07)00065-5

doi: 10.1016/j.beha.2007.08.003

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 613-624 , December 2007

Article Tools

* Image Usage & Resolution